Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2012-06-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/annrheumdis-2012-201601PMID 22730366
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis

  2010cited by this paper
• The risk of infections with biologic therapies for rheumatoid arthritis.

  2010cited by this paper
• Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

  2010cited by this paper
• Role of Th17 cells in human autoimmune arthritis.

  2010cited by this paper
• Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy

  2009cited by this paper
• Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases

  2009cited by this paper
• IL-17 as a future therapeutic target for rheumatoid arthritis

  2009cited by this paper
• Interleukin-17 and type 17 helper T cells.

  2009cited by this paper
• A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome.

  2008cited by this paper
• Mortality in rheumatoid arthritis: 2008 update.

  2008cited by this paper
• Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

  2006cited by this paper
• Interleukin-17: a mediator of inflammatory responses

  2004influential reference
• Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.

  2004cited by this paper
• Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy.

  2003cited by this paper
• Interleukin-17 family and IL-17 receptors.

  2003cited by this paper
• Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice 1

  2003cited by this paper
• Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein.

  2002cited by this paper
• Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.

  2002cited by this paper
• IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis

  2001cited by this paper
• Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo.

  2001cited by this paper
• IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

  1999cited by this paper
• IL-17 Stimulates the Production and Expression of Proinflammatory Cytokines, IL-β and TNF-α, by Human Macrophages

  1998cited by this paper
• IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages.

  1998cited by this paper
• T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines

  1996cited by this paper
• The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis.

  1992cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper

• Human CD4+ T cells regulate peripheral immune responses in rheumatoid arthritis via insulin-like growth factor-like family member 2.

  2025cites this paper
• FGF7 as an essential mediator for the onset of ankylosing enthesitis related to psoriatic dermatitis

  2025cites this paper
• The IL-23/IL-17/NF-κB Signaling Pathway in Rheumatoid Arthritis: Molecular Mechanisms and Therapeutic Agents.

  2025cites this paper
• Beta adrenergic signaling as a therapeutic target for autoimmunity.

  2025cites this paper
• Beta Adrenergic Signaling as a Therapeutic Target for Autoimmunity

  2025cites this paper
• T Cell Dysregulation in Rheumatoid Arthritis: from Genetic Susceptibility to Established Disease

  2025cites this paper
• TH17 cells converted into exTH17 cells sustain rheumatoid-like IL-17-independent inflammatory arthritis.

  2025cites this paper
• Clinical Considerations for the Use of Biologic Agents in Psoriasis Patients With a History of Lymphoma.

  2025cites this paper
• Constrained Best Arm Identification with Tests for Feasibility

  2025cites this paper
• Aberrant T follicular helper cells generated by TH17 cell plasticity in the gut promote extraintestinal autoimmunity

  2025cites this paper
• Balancing Performance and Costs in Best Arm Identification

  2025influential citation
• Stochastically Constrained Best Arm Identification with Thompson Sampling

  2025cites this paper
• Multifunctional nanoparticle-mediated combining therapy for human diseases

  2024cites this paper
• The IL-17 pathway as a target in giant cell arteritis

  2024cites this paper
• Reward Maximization for Pure Exploration: Minimax Optimal Good Arm Identification for Nonparametric Multi-Armed Bandits

  2024cites this paper
• Current Concepts in the Treatment of Giant Cell Tumor of Bone: An Update

  2024cites this paper
• From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?

  2024cites this paper
• The role of interleukin 17 in the pathogenesis of rheumatoid arthritis. Are there any prospects for the use of IL-17 inhibitors?

  2023cites this paper
• Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion

  2023cites this paper
• Automated clustering reveals CD4+ T cell subset imbalances in rheumatoid arthritis

  2023cites this paper
• Emerging roles and therapeutic implications of HDAC2 and IL-17A in steroid-resistant asthma

  2023cites this paper
• IL-17 cytokines preferentially act on naïve CD4+ T cells with the IL-17AF heterodimer inducing the greatest functional changes

  2023cites this paper
• Design and Evaluation of Continentalic Acid Encapsulated Transfersomal Gel and Profiling of its Anti-arthritis Activity

  2023cites this paper
• Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders.

  2023cites this paper
• Improving the Knowledge Gradient Algorithm

  2023cites this paper
• Histopathology of Psoriatic Arthritis Synovium—A Narrative Review

  2022cites this paper
• The Effect of Anti-rheumatic Drugs on the Skeleton

  2022cites this paper
• A Systematic Literature Review of Injection Site Pain Perception in Adult Patients Treated with Citrate-Free and Citrate-Containing Biologic Agents

  2022cites this paper
• CD4+ T cell subset imbalance in rheumatoid arthritis: a case-control study

  2022cites this paper
• No Significant Effects of IL-23 on Initiating and Perpetuating the Axial Spondyloarthritis: The Reasons for the Failure of IL-23 Inhibitors

  2022cites this paper
• Rheumatoid arthritis: current therapeutics compendium

  2022cites this paper
• Pak2-mediated phosphorylation promotes RORγt ubiquitination and inhibits colonic inflammation

  2022cites this paper
• CD4 + T cell subset imbalances in rheumatoid arthritis An unsupervised clustering algorithm identifies rare T helper cell subset aberrations

  2022cites this paper
• Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research

  2022cites this paper
• Prospective multicentre study of experience in real-world clinical practice in monitoring reported outcome measures (PROMs) of patient with a diagnosis of psoriatic and/or spondyloarthritis and initiating treatment with secukinumab.

  2022cites this paper
• Inflammation and Bone Metabolism in Rheumatoid Arthritis: Molecular Mechanisms of Joint Destruction and Pharmacological Treatments

  2022cites this paper
• Strategies for Safe Multi-Armed Bandits with Logarithmic Regret and Risk

  2022cites this paper
• Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs.

  2021cites this paper
• Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders

  2021cites this paper
• MicroRNA-10b promotes arthritis development by disrupting CD4+ T cell subtypes

  2021cites this paper
• Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials

  2021cites this paper
• Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis

  2021cites this paper
• Association of microRNA-125a with the clinical features, disease activity and inflammatory cytokines of juvenile-onset lupus patients

  2021cites this paper
• Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab

  2021cites this paper
• Cyanidin attenuates IL-17A cytokine signaling mediated monocyte migration and differentiation into mature osteoclasts in rheumatoid arthritis.

  2021cites this paper
• Distinct roles of interleukin-17 and T helper 17 cells among autoimmune diseases

  2021cites this paper
• Current Concepts in the Treatment of Giant Cell Tumors of Bone

  2021cites this paper
• Biologic therapies for the treatment of rheumatoid arthritis

  2021influential citation
• Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis.

  2021cites this paper
• Differentiating Psoriatic Arthritis from Osteoarthritis and Rheumatoid Arthritis: A Narrative Review and Guide for Advanced Practice Providers

  2021cites this paper
• Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview

  2021cites this paper
• Serum interleukin-17 expression in a group of Egyptian patients with juvenile systemic lupus erythematosus

  2021cites this paper
• Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis

  2021cites this paper
• Comprehensive TCR repertoire analysis of CD4+ T-cell subsets in rheumatoid arthritis.

  2020cites this paper
• Tocotrienol regulates osteoclastogenesis in rheumatoid arthritis

  2020cites this paper
• The IL-17/Th17 Axis as a Therapeutic Target in Periodontitis

  2020cites this paper
• Rheumatoid Arthritis in the View of Osteoimmunology

  2020cites this paper
• Prospective multicentre study of experience in real-world clinical practice in monitoring reported outcome measures (PROMs) of patient with a diagnosis of psoriatic and/or spondyloarthritis and initiating treatment with secukinumab.

  2020cites this paper
• Current and novel therapeutic targets in the treatment of rheumatoid arthritis

  2020cites this paper
• 14-3-3ζ–TRAF5 axis governs interleukin-17A signaling

  2020cites this paper
• Emerging Therapies in Periodontics

  2020cites this paper
• Infectious Complications of Biological Agents

  2020cites this paper
• Systematic Review and Meta-analysis Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials RHEUMATOLOGY

  2020cites this paper
• Inflammatory Arthritis: Rheumatoid Arthritis

  2020cites this paper
• Network Pharmacology to Identify the Pharmacological Mechanisms of a Traditional Chinese Medicine Derived from Trachelospermum jasminoides in Patients with Rheumatoid Arthritis

  2020cites this paper
• Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis

  2020cites this paper
• Interleukin-17 in rheumatoid arthritis: Trials and tribulations

  2020cites this paper
• Molecular control of pathogenic Th17 cells in autoimmune diseases.

  2020cites this paper
• Stellenwert von interleukingerichteten Therapien bei Autoimmunkrankheiten

  2020cites this paper
• Psoriatic arthritis in childhood: A commentary on the controversy.

  2020cites this paper
• Estudio prospectivo multicéntrico de experiencia en práctica clínica real en el control de medidas de desenlace reportadas por el paciente (PRO) diagnosticado de artritis psoriásica y/o espondiloartritis y que inicia tratamiento con secukinumab

  2020cites this paper
• Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases

  2019cites this paper
• Role of Interleukin-17 in immunopathology of chronic and aggressive periodontitis

  2019cites this paper
• Systematic review with meta‐analysis: risk of new onset IBD with the use of anti‐interleukin‐17 agents

  2019cites this paper
• Regulation of Immune Responses and Chronic Inflammation by Fibroblast-Like Synoviocytes

  2019cites this paper
• Rheumatoid arthritis: ‘melting pot’ of T helper subsets

  2019cites this paper
• Meta-analysis of IL-17 inhibitors in two populations of rheumatoid arthritis patients: biologic-naïve or tumor necrosis factor inhibitor inadequate responders

  2019cites this paper
• Silencing RORγt in Human CD4+ T cells with CD30 aptamer-RORγt shRNA Chimera

  2019cites this paper
• Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials

  2019cites this paper
• Cytokine targeting in rheumatoid arthritis.

  2019cites this paper
• Quantifying circulating Th17 cells by qPCR: potential as diagnostic biomarker for rheumatoid arthritis.

  2019cites this paper
• Mesenchymal Stem Cells Improve Rheumatoid Arthritis Progression by Controlling Memory T Cell Response

  2019cites this paper
• Running head: CRP, IL-17A, and IL-17F responsive to ustekinumab in PsA Serum CRP, IL-17A, and IL-17F levels are responsive to ustekinumab in psoriatic arthritis: lessons from the PSUMMIT study programme

  2019cites this paper
• Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases

  2019cites this paper
• Applications of RNA interference in the treatment of arthritis.

  2019cites this paper
• The pathogenicity of Th17 cells in autoimmune diseases

  2019cites this paper
• Humanized Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Cell-Based Therapies

  2019cites this paper
• Elevated expression of interleukin‐37 in patients with rheumatoid arthritis

  2019cites this paper
• Quercetin, a Plant Polyphenol, Has Potential for the Prevention of Bone Destruction in Rheumatoid Arthritis

  2019cites this paper
• Immunological Basis of Inflammatory Arthritides

  2019cites this paper
• Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis

  2019cites this paper
• Responsiveness of Serum C‐Reactive Protein, Interleukin‐17A, and Interleukin‐17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double‐Blind, Placebo‐Controlled Trials

  2019cites this paper
• Bedside to bench: defining the immunopathogenesis of psoriatic arthritis

  2019cites this paper
• Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials.

  2019cites this paper
• Role of Biological Agents in Treatment of Rheumatoid Arthritis.

  2019cites this paper
• CCR6+ group 3 innate lymphoid cells accumulate in inflamed joints in rheumatoid arthritis and produce Th17 cytokines

  2019cites this paper
• Sur la notion d'optimalité dans les problèmes de bandit stochastique

  2018influential citation
• TARGETING INTERLEUKIN 17 IN THE TREATMENT OF RHEUMATOID ARTHRITIS

  2018cites this paper
• Population Pharmacokinetics of the TNF‐α and IL‐17A Dual‐Variable Domain Antibody ABT‐122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials

  2018cites this paper
• Implicaciones terapéuticas de la interleucina-17 en otras enfermedades y comorbilidades

  2018cites this paper